Foxx Development (NASDAQ:FOXX – Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($5.19) EPS for the quarter, FiscalAI reports. The company had revenue of $8.67 million for the quarter.
Foxx Development Trading Up 0.5%
FOXX stock opened at $3.96 on Friday. The company has a market cap of $27.76 million, a P/E ratio of -0.58 and a beta of -0.10. Foxx Development has a 52 week low of $1.71 and a 52 week high of $8.88. The company’s 50-day moving average price is $4.87 and its 200 day moving average price is $4.53.
Hedge Funds Weigh In On Foxx Development
An institutional investor recently bought a new position in Foxx Development stock. Citadel Advisors LLC bought a new position in shares of Foxx Development Holdings Inc. (NASDAQ:FOXX – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 12,025 shares of the company’s stock, valued at approximately $57,000. Citadel Advisors LLC owned about 0.18% of Foxx Development at the end of the most recent quarter. 60.44% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Read Our Latest Stock Report on Foxx Development
Foxx Development Company Profile
Foxx Development, Inc (NASDAQ: FOXX) operates as a contract manufacturer specializing in the design, assembly and distribution of medical devices and components. The company’s core business centers on phlebotomy and blood collection products, serving clinical laboratories, hospitals and diagnostic testing facilities. Its product portfolio includes evacuated blood collection tubes, safety-engineered winged blood collection sets, syringes and ancillary devices used in specimen collection and handling.
Founded in North Carolina, Foxx Development maintains a manufacturing and distribution campus in Apex, where it integrates engineering, quality control and regulatory compliance under one roof.
Read More
- Five stocks we like better than Foxx Development
- Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half
- Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish
- Intuit’s Great SaaS Reset: Fired By AI
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
Receive News & Ratings for Foxx Development Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foxx Development and related companies with MarketBeat.com's FREE daily email newsletter.
